GB1575646A - Therapeutic compositions and their administration - Google Patents
Therapeutic compositions and their administration Download PDFInfo
- Publication number
- GB1575646A GB1575646A GB1063877A GB1063877A GB1575646A GB 1575646 A GB1575646 A GB 1575646A GB 1063877 A GB1063877 A GB 1063877A GB 1063877 A GB1063877 A GB 1063877A GB 1575646 A GB1575646 A GB 1575646A
- Authority
- GB
- United Kingdom
- Prior art keywords
- keto
- alpha
- analog
- composition
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims description 145
- 230000001225 therapeutic effect Effects 0.000 title description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 139
- 229910052757 nitrogen Inorganic materials 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 70
- 150000001413 amino acids Chemical group 0.000 claims description 63
- 150000004715 keto acids Chemical class 0.000 claims description 52
- 235000020776 essential amino acid Nutrition 0.000 claims description 40
- 239000003797 essential amino acid Substances 0.000 claims description 40
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 39
- 150000001261 hydroxy acids Chemical class 0.000 claims description 39
- 229910052708 sodium Inorganic materials 0.000 claims description 38
- 239000011734 sodium Substances 0.000 claims description 38
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 33
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 29
- 229960000310 isoleucine Drugs 0.000 claims description 29
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 29
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 27
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 26
- 239000011575 calcium Substances 0.000 claims description 26
- 229960002885 histidine Drugs 0.000 claims description 26
- 229930182817 methionine Natural products 0.000 claims description 26
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 25
- 229910052791 calcium Inorganic materials 0.000 claims description 25
- 125000000468 ketone group Chemical group 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 18
- 229960004799 tryptophan Drugs 0.000 claims description 18
- 239000004474 valine Substances 0.000 claims description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 17
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 17
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 17
- 208000017169 kidney disease Diseases 0.000 claims description 16
- 239000004473 Threonine Substances 0.000 claims description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 229960002898 threonine Drugs 0.000 claims description 13
- 238000001243 protein synthesis Methods 0.000 claims description 11
- 230000014616 translation Effects 0.000 claims description 11
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 10
- 238000007911 parenteral administration Methods 0.000 claims description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 9
- 229930194542 Keto Natural products 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- PICCHNWCTUUCAQ-UHFFFAOYSA-N 2-hydroxypentanethioic s-acid Chemical compound CCCC(O)C(O)=S PICCHNWCTUUCAQ-UHFFFAOYSA-N 0.000 claims description 7
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 150000004716 alpha keto acids Chemical class 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 229960005357 lysine acetate Drugs 0.000 claims description 5
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 claims description 4
- WQZNGJIBHXYVNW-UHFFFAOYSA-L calcium;4-methyl-2-oxopentanoate Chemical compound [Ca+2].CC(C)CC(=O)C([O-])=O.CC(C)CC(=O)C([O-])=O WQZNGJIBHXYVNW-UHFFFAOYSA-L 0.000 claims description 4
- VOXXWSYKYCBWHO-MRVPVSSYSA-N (R)-3-phenyllactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-MRVPVSSYSA-N 0.000 claims description 3
- RILPIWOPNGRASR-AKGZTFGVSA-N (2s)-2-hydroxy-3-methylpentanoic acid Chemical compound CCC(C)[C@H](O)C(O)=O RILPIWOPNGRASR-AKGZTFGVSA-N 0.000 claims description 2
- JVQYSWDUAOAHFM-BYPYZUCNSA-N (S)-3-methyl-2-oxovaleric acid Chemical compound CC[C@H](C)C(=O)C(O)=O JVQYSWDUAOAHFM-BYPYZUCNSA-N 0.000 claims description 2
- BKMMOJVSLBZNTK-UHFFFAOYSA-L calcium;2-oxo-3-phenylpropanoate Chemical compound [Ca+2].[O-]C(=O)C(=O)CC1=CC=CC=C1.[O-]C(=O)C(=O)CC1=CC=CC=C1 BKMMOJVSLBZNTK-UHFFFAOYSA-L 0.000 claims description 2
- 150000002519 isoleucine derivatives Chemical class 0.000 claims description 2
- 150000002614 leucines Chemical class 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000002742 methionines Chemical class 0.000 claims 1
- 150000002994 phenylalanines Chemical class 0.000 claims 1
- 150000003680 valines Chemical class 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 100
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 76
- 229940024606 amino acid Drugs 0.000 description 63
- 235000001014 amino acid Nutrition 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 54
- 108090000623 proteins and genes Proteins 0.000 description 54
- 239000004202 carbamide Substances 0.000 description 50
- 229910021529 ammonia Inorganic materials 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 159000000007 calcium salts Chemical class 0.000 description 22
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 17
- 206010020575 Hyperammonaemia Diseases 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 14
- 208000019423 liver disease Diseases 0.000 description 14
- 239000004475 Arginine Substances 0.000 description 13
- 229960003121 arginine Drugs 0.000 description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 13
- 235000009697 arginine Nutrition 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- 235000014304 histidine Nutrition 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 208000001647 Renal Insufficiency Diseases 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 201000006370 kidney failure Diseases 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 102000015781 Dietary Proteins Human genes 0.000 description 10
- 108010010256 Dietary Proteins Proteins 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 229940109239 creatinine Drugs 0.000 description 10
- 235000021245 dietary protein Nutrition 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000037157 Azotemia Diseases 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 230000004075 alteration Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000009852 uremia Diseases 0.000 description 8
- -1 Amino Acid Hydroxy-Acid Chemical class 0.000 description 7
- 208000008425 Protein deficiency Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002699 waste material Substances 0.000 description 7
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 6
- 230000000322 hemodialysis Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 208000007386 hepatic encephalopathy Diseases 0.000 description 5
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000021075 protein intake Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 3
- QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 201000011297 Citrullinemia Diseases 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 235000020905 low-protein-diet Nutrition 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005891 transamination reaction Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 2
- 244000118350 Andrographis paniculata Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 description 1
- KFSJYZYQSZKRRQ-BYPYZUCNSA-N (2s)-2-(hydroxyamino)-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@H](NO)C(O)=O KFSJYZYQSZKRRQ-BYPYZUCNSA-N 0.000 description 1
- MBGQSVGJHSCMFS-BYPYZUCNSA-N (2s)-3-methyl-2-nitrosobutanoic acid Chemical compound CC(C)[C@H](N=O)C(O)=O MBGQSVGJHSCMFS-BYPYZUCNSA-N 0.000 description 1
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 1
- LOUGYXZSURQALL-UHFFFAOYSA-N 2,3-dihydroxybutanoic acid Chemical compound CC(O)C(O)C(O)=O LOUGYXZSURQALL-UHFFFAOYSA-N 0.000 description 1
- LIOSZYBFCUDMNY-UHFFFAOYSA-N 2-hydroxy-2-phenylpropanoic acid 2-hydroxy-3-phenylpropanoic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1.OC(=O)C(O)CC1=CC=CC=C1 LIOSZYBFCUDMNY-UHFFFAOYSA-N 0.000 description 1
- 239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 1
- BBOOMRFBUGNJOS-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CC1=NC=CN1 BBOOMRFBUGNJOS-UHFFFAOYSA-N 0.000 description 1
- VOXXWSYKYCBWHO-UHFFFAOYSA-M 3-phenyllactate Chemical compound [O-]C(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-M 0.000 description 1
- OQYTWFXJFZXOLB-UHFFFAOYSA-N 4-(diaminomethylideneamino)-2-oxopentanoic acid Chemical compound NC(N)=NC(C)CC(=O)C(O)=O OQYTWFXJFZXOLB-UHFFFAOYSA-N 0.000 description 1
- KCRMLLUEFBFZHM-UHFFFAOYSA-N 4-amino-2-hydroxyhexanoic acid Chemical compound CCC(N)CC(O)C(O)=O KCRMLLUEFBFZHM-UHFFFAOYSA-N 0.000 description 1
- VFGWNXBIUOYMNX-UHFFFAOYSA-N 4-amino-2-oxohexanoic acid Chemical compound CCC(N)CC(=O)C(O)=O VFGWNXBIUOYMNX-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000035943 Aphagia Diseases 0.000 description 1
- 206010062695 Arginase deficiency Diseases 0.000 description 1
- 208000034318 Argininemia Diseases 0.000 description 1
- 206010058298 Argininosuccinate synthetase deficiency Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 206010058297 Carbamoyl phosphate synthetase deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- OHIYMVFLQXTZAW-UFYCRDLUSA-N Phe-Met-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OHIYMVFLQXTZAW-UFYCRDLUSA-N 0.000 description 1
- DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000799 cathartic agent Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000011286 hyperargininemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- IFSCKRWNXKWTLR-UHFFFAOYSA-M sodium;4-methylsulfanyl-2-oxobutanoate Chemical compound [Na+].CSCCC(=O)C([O-])=O IFSCKRWNXKWTLR-UHFFFAOYSA-M 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- ZJHHPAUQMCHPRB-UHFFFAOYSA-N urea urea Chemical compound NC(N)=O.NC(N)=O ZJHHPAUQMCHPRB-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- QWZIITCYKKSZGN-UHFFFAOYSA-N xi-3-Hydroxy-2-oxobutanoic acid Chemical compound CC(O)C(=O)C(O)=O QWZIITCYKKSZGN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/669,588 US4100160A (en) | 1974-04-15 | 1976-03-23 | Therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1575646A true GB1575646A (en) | 1980-09-24 |
Family
ID=24686912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1063877A Expired GB1575646A (en) | 1976-03-23 | 1977-03-14 | Therapeutic compositions and their administration |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2712777A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2315916A2 (enrdf_load_stackoverflow) |
| GB (1) | GB1575646A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072078A3 (de) * | 2001-03-13 | 2002-12-12 | Erich Eigenbrodt | Verwendung von zuckerphosphaten, aminosäure und deren analogen we z. b. carbomethoxypropionylcyanid zur gewichtsreduzierung oder diabeteskomplikationen |
| WO2002072527A3 (de) * | 2001-03-13 | 2003-01-16 | Stefan Muellner | 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung |
| WO2002072534A3 (de) * | 2001-03-13 | 2003-08-28 | Erich Eigenbrodt | 1-butansäurederivate, pharmazeutische zusammensetzungen enthaltend solche derivate und verwendungen solcher derivate |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
| FR2618331B1 (fr) * | 1987-07-23 | 1991-10-04 | Synthelabo | Compositions pharmaceutiques utiles pour le traitement de l'uremie |
| DE3943424A1 (de) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Infusions- und injektionsloesung zur intravenoesen verabreichung |
| FR2695317B1 (fr) * | 1992-09-07 | 1995-03-10 | Monal Lab | Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant. |
| DE102007016715A1 (de) * | 2007-04-04 | 2008-10-09 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren |
| DE102009016119A1 (de) * | 2009-04-03 | 2010-10-14 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie |
-
1976
- 1976-08-06 FR FR7624203A patent/FR2315916A2/fr active Granted
-
1977
- 1977-03-14 GB GB1063877A patent/GB1575646A/en not_active Expired
- 1977-03-23 DE DE19772712777 patent/DE2712777A1/de not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072078A3 (de) * | 2001-03-13 | 2002-12-12 | Erich Eigenbrodt | Verwendung von zuckerphosphaten, aminosäure und deren analogen we z. b. carbomethoxypropionylcyanid zur gewichtsreduzierung oder diabeteskomplikationen |
| WO2002072527A3 (de) * | 2001-03-13 | 2003-01-16 | Stefan Muellner | 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung |
| WO2002072534A3 (de) * | 2001-03-13 | 2003-08-28 | Erich Eigenbrodt | 1-butansäurederivate, pharmazeutische zusammensetzungen enthaltend solche derivate und verwendungen solcher derivate |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2315916A2 (fr) | 1977-01-28 |
| FR2315916B2 (enrdf_load_stackoverflow) | 1979-09-14 |
| DE2712777A1 (de) | 1977-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4100160A (en) | Therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation | |
| US4100293A (en) | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids | |
| JP4125791B2 (ja) | 糖尿病患者用医療栄養物 | |
| US5084482A (en) | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds | |
| EP3219315B1 (en) | Mixture of carboxylic acids for treating patients with kidney failure | |
| Jones et al. | Oral essential aminoacid and ketoacid supplements in children with chronic renal failure | |
| US5698230A (en) | Amino acid solutions for treatment of peritoneal dialysis patients | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| Rebouche | Effect of dietary carnitine isomers and γ-butyrobetaine on L-carnitine biosynthesis and metabolism in the rat | |
| EP1374863B1 (en) | Amino acid compositions for ameliorating liver failure | |
| Blackburn et al. | Criteria for choosing amino acid therapy in acute renal failure | |
| Kahler et al. | Parenteral nutrition in propionic and methylmalonic acidemia | |
| Mullen et al. | Role of nutrition in hepatic encephalopathy | |
| GB1575646A (en) | Therapeutic compositions and their administration | |
| US5122515A (en) | Nutrient composition containing dipeptides and method for administering the same | |
| US4902718A (en) | Calcium homeostasis compositions and methods for controlling calcium metabolism | |
| IL42726A (en) | Composition for promotion of protein synthesis and suppression of urea formation in the body | |
| JPS61501558A (ja) | 中および長鎖トリグリセライドの非経口栄養補給 | |
| AU2004254154B2 (en) | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition | |
| PT656178E (pt) | Composicoes nutricionais para gestao do metabolismo do azoto | |
| Batshaw et al. | Long-term management of a case of carbamyl phosphate synthetase deficiency using ketoanalogues and hydroxyanalogues of essential amino acids | |
| Richards | Protein metabolism in uraemia | |
| EP1200077A2 (en) | L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases | |
| Tedesco et al. | Free amino acids in Citrullus vulgaris (watermelon) | |
| KR960016569B1 (ko) | 알라닌 및 글루타민 함유 식품 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |